
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Amyloidosis pathophysiology
Introduction
Overview
Overview
Amyloid is an abnormal insoluble extracellular protein that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes. In systemic amyloidosis, amyloid gradually accumulate and amyloid deposition is widespread in the viscera, blood vessel walls, and in the different connective tissues. Primary (AL) amyloidosis) is the most common type of amyloidosis. It results from aggregation and deposition of monoclonal immunoglobulin (Ig) light chains that usually produced by plasma cell clones. Secondary amyloidosis is associated with chronic inflammation (such as tuberculosis or rheumatoid arthritis). Hereditary (or familial) amyloidosis are autosomal dominant diseases that inherited variant proteins cause the production and deposition of amyloid fibrils. Some neurodegenerative disorders such as Parkinson’s disease, Alzheimer, and Huntington’s disease may occur in localised amyloidosis. On microscopic pathology, typical green birefringence under polarized light after Congo red staining (appears in red under normal light).
Pathophysiology
Pathophysiology
- Amyloid is an abnormal insoluble extracellular protein that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes.[1]
- These abnormal amyloids are derived from misfolding and aggregation of normally soluble proteins.
- Amyloid deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.[2]
Systemic Amyloidosis
- In systemic amyloidosis, amyloid gradually accumulates and amyloid deposition is widespread in the viscera, blood vessel walls, and different connective tissues.[3][4]
Primary Amyloidosis (AL)
- Primary (AL) amyloidosis) is the most common type of amyloidosis.[5]
- It results from aggregation and deposition of monoclonal immunoglobulin (Ig) light chains that are usually produced by plasma cell clones.
- Change in the secondary structure or tertiary structure of a monoclonal light chain results in abnormal folding of the light chain that abnormally form amyloid fibrils.
- This type of amyloidosis most frequently involve the kidney (nephrotic syndrome) and the heart.
- In primary (AL) amyloidosis survival rate depends on:
- Type of organ involvement (amyloid heart disease is the main prognostic factor)
- The severity of different organ involvement
- Hematological response to treatment
- The median survival of patients with AL amyloidosis is approximately 3.8 years.
Secondary Amyloidosis (AA)
- Secondary amyloidosis occurs as a reaction to an existing illness.
- Secondary amyloidosis is associated with chronic inflammation (such as tuberculosis or rheumatoid arthritis).[6]
- Secondary or reactive amyloidosis (AA) comprises approximately 45% of the systemic amyloidoses.
- Pathogenesis of secondary amyloidosis is multifactorial, including:
- Primary structure of the precursor protein
- Acute phase response
- Nonfibril proteins (amyloid P component, apo E, GAGs, proteoglycans and basement membrane proteins)
- Receptors
- Lipid metabolism
- Proteases
Hereditary Amyloidosis
- Hereditary amyloidosis is an autosomal dominant disorder.[7]
- It can have a heterogeneous nature of presentation and can be complicated by significant disability and mortality.[8]
- Inherited variant proteins cause the production and deposition of amyloid fibrils.[6]
- Hereditary amyloidosis is due to amyloidogenic mutations and the subsequent deposition of amyloids which include:
Organ-specific Amyloidosis
- In this type of amyloidosis, amyloid deposition occurs only in the organ of origin or tissue of precursor protein.
- Neurodegenerative disorders, such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease, may occur in localized amyloidosis.
- Localized amyloidoses can develop due to the deposition of intracellular and/or extracellular amyloid.
- Huntington’s disease: intracellular protein deposition
- Parkinson’s disease: intracellular protein deposition
- Alzheimer’s disease: intracellular (Tau protein fibrils) and extracellular (amyloid Ξ² fibrils) deposition
Genetics
Genetics
Hereditary Amyloidosis
- Hereditary amyloidosis involves mutations in the following genes:[9]
- LYZ gene
- Fibrinogen A alpha polypeptide gene
- FGA gene
- APOA1 gene
- Lysozyme gene
- B2M gene
Primary Localized Cutaneous Amyloidosis
- Primary localized cutaneous amyloidosis is inherited in autosomal dominant manner.[10]
- Primary localized cutaneous amyloidosis involves mutations in the following genes:[11]
- OSMR gene
Associated Conditions
Associated Conditions
Conditions associated with amyloidosis include:[12]
- MEN2A
Gross Pathology
Gross Pathology
On gross pathology, the organs affected by amyloidosis can be characterized by the following features:
- Porcelain like or waxy appearance
- Enlargement
Images



Microscopic Pathology
Microscopic Pathology
On microscopic histopathological analysis, amyloidosis is characterized by:[6][16]
- Green birefringence under polarized light after Congo red staining (appears red under normal light)
- Linear non-branching fibrils (indefinite length with an approximately same diameter)
- Distinct X-ray diffraction pattern consistent with Pauling’s model of a cross-beta fibril
Images



References
References
- β Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). “Systemic amyloidosis”. Lancet. 387 (10038): 2641β2654. doi:10.1016/S0140-6736(15)01274-X. PMIDΒ 26719234.
- β Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). “Systemic amyloidosis”. Lancet. 387 (10038): 2641β2654. doi:10.1016/S0140-6736(15)01274-X. PMIDΒ 26719234.
- β Baker KR, Rice L (2012). “The amyloidoses: clinical features, diagnosis and treatment”. Methodist Debakey Cardiovasc J. 8 (3): 3β7. PMCΒ 3487569. PMIDΒ 23227278.
- β Pepys MB (2006). “Amyloidosis”. Annu. Rev. Med. 57: 223β41. doi:10.1146/annurev.med.57.121304.131243. PMIDΒ 16409147.
- β Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). “Systemic amyloidosis”. Lancet. 387 (10038): 2641β2654. doi:10.1016/S0140-6736(15)01274-X. PMIDΒ 26719234.
- β 6.0 6.1 6.2 Khan MF, Falk RH (November 2001). “Amyloidosis”. Postgrad Med J. 77 (913): 686β93. PMCΒ 1742163. PMIDΒ 11677276.
- β Hund E, Linke RP, Willig F, Grau A (February 2001). “Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment”. Neurology. 56 (4): 431β5. doi:10.1212/wnl.56.4.431. PMIDΒ 11261421.
- β Gertz MA (June 2017). “Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges”. Am J Manag Care. 23 (7 Suppl): S107βS112. PMIDΒ 28978215.
- β Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ (April 1993). “Human lysozyme gene mutations cause hereditary systemic amyloidosis”. Nature. 362 (6420): 553β7. doi:10.1038/362553a0. PMIDΒ 8464497.
- β Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA (January 2008). “Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis”. Am. J. Hum. Genet. 82 (1): 73β80. doi:10.1016/j.ajhg.2007.09.002. PMCΒ 2253984. PMIDΒ 18179886.
- β Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA (January 2008). “Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis”. Am. J. Hum. Genet. 82 (1): 73β80. doi:10.1016/j.ajhg.2007.09.002. PMCΒ 2253984. PMIDΒ 18179886.
- β Hofstra RM, Sijmons RH, Stelwagen T, Stulp RP, Kousseff BG, Lips CJ, Steijlen PM, Van Voorst Vader PC, Buys CH (August 1996). “RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia”. J. Invest. Dermatol. 107 (2): 215β8. doi:10.1111/1523-1747.ep12329651. PMIDΒ 8757765.
- β By Yale Rosen from USA – Amyloidosis, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=31127928
- β By Ed Uthman, MD – https://www.flickr.com/photos/euthman/377537238/, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=1629764
- β By Ed Uthman, MD – https://www.flickr.com/photos/euthman/377538012/, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=1629740
- β RΓΆcken C, Shakespeare A (February 2002). “Pathology, diagnosis and pathogenesis of AA amyloidosis”. Virchows Arch. 440 (2): 111β122. doi:10.1007/s00428-001-0582-9. PMIDΒ 11964039.
- β By Michael Feldman, MD, PhDUniversity of Pennsylvania School of Medicine – http://www.healcentral.org/healapp/showMetadata?metadataId=38717, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=870218
- β By Ed Uthman, MD – https://www.flickr.com/photos/euthman/377559787/, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=1629716
- β By Ed Uthman, MD – https://www.flickr.com/photos/euthman/377559955/, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=1629705
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]Sabawoon Mirwais, M.B.B.S, M.D.[3]
